DOCSLIB.ORG

Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase 2 BMP6 0.405 6p24-p23 bone morphogenetic protein 6 TTC39C 0.402 18q11.2 tetratricopeptide repeat domain 39C CATSPERB 0.401 14q32.12 catsper channel auxiliary subunit beta XBP1 0.401 22q12.1|22q12X-box binding protein 1 PIM3 0.398 22q13 Pim-3 proto-oncogene, serine/threonine kinase ID1 0.396 20q11 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein AKR1C2 0.396 10p15-p14 aldo-keto reductase family 1, member C2 ATP2A2 0.395 12q24.11 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 EPAS1 0.395 2p21-p16 endothelial PAS domain protein 1 C2CD4D 0.393 1q21.3 C2 calcium-dependent domain containing 4D SHTN1 0.391 10q25.3 shootin 1 GK 0.391 Xp21.3 glycerol kinase PDIA3P1 0.385 1q21.1 protein disulfide isomerase family A, member 3 pseudogene 1 CHMP1B 0.385 18p11.21 charged multivesicular body protein 1B PCSK9 0.384 1p32.3 proprotein convertase subtilisin/kexin type 9 PDIA3 0.384 15q15 protein disulfide isomerase family A, member 3 DACT2 0.381 6q27 dishevelled-binding antagonist of beta-catenin 2 HSP90B1 0.38 12q24.2-q24.3heat shock protein 90kDa beta (Grp94), member 1 PRR26 0.379 10p15.3 proline rich 26 MISP 0.378 19p13.3 mitotic spindle positioning KSR1 0.375 17q11.2 kinase suppressor of ras 1 TC2N 0.375 14q32.12 tandem C2 domains, nuclear CPE 0.374 4q32.3 carboxypeptidase E SCARB1 0.372 12q24.31 scavenger receptor class B, member 1 SPINK1 0.372 5q32 serine peptidase inhibitor, Kazal type 1 LGSN 0.371 6pter-q22.33lengsin, lens protein with glutamine synthetase domain FRAT2 0.37 10q24.1 frequently rearranged in advanced T-cell lymphomas 2 GK3P 0.369 4q32.1 glycerol kinase 3 pseudogene AKR1C1 0.369 10p15-p14 aldo-keto reductase family 1, member C1 MSMB 0.367 10q11.2 microseminoprotein, beta- FAAH2 0.366 Xp11.21 fatty acid amide hydrolase 2 SEMA4G 0.366 10q24.31 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4G HHIPL2 0.364 1q41 HHIP-like 2 LINC00319 0.363 21q22.3 long intergenic non-protein coding RNA 319 PPP1R3B 0.363 8p23.1 protein phosphatase 1, regulatory subunit 3B SLC7A11 0.361 4q28.3 solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11 NR4A1 0.361 12q13 nuclear receptor subfamily 4, group A, member 1 MAP2K6 0.359 17q24.3 mitogen-activated protein kinase kinase 6 BASP1 0.358 5p15.1 brain abundant, membrane attached signal protein 1 CARD14 0.357 17q25 caspase recruitment domain family, member 14 ITIH2 0.357 10p15 inter-alpha-trypsin inhibitor heavy chain 2 GABARAPL10.355 12p13.2 GABA(A) receptor-associated protein like 1 MAPK4 0.355 18q21.1 mitogen-activated protein kinase 4 MTMR7 0.355 8p22 myotubularin related protein 7 RASD1 0.353 17p11.2 RAS, dexamethasone-induced 1 PLEKHG2 0.352 19q13.2 pleckstrin homology domain containing, family G (with RhoGef domain) member 2 PITPNC1 0.352 17q24.2 phosphatidylinositol transfer protein, cytoplasmic 1 CLPX 0.352 15q22.31 caseinolytic mitochondrial matrix peptidase chaperone subunit HNF1A 0.351 12q24.2 HNF1 homeobox A FXR2 0.35 17p13.1 fragile X mental retardation, autosomal homolog 2 BHLHA15 0.349 7q21.3 basic helix-loop-helix family, member a15 CHML 0.349 1q43 choroideremia-like (Rab escort protein 2) PDE3B 0.348 11p15.1 phosphodiesterase 3B, cGMP-inhibited CABYR 0.348 18q11.2 calcium binding tyrosine-(Y)-phosphorylation regulated TRIM31 0.348 6p21.3 tripartite motif containing 31 AVPI1 0.347 10q24.2 arginine vasopressin-induced 1 RFK 0.347 9q21.13 riboflavin kinase TMEM254 0.347 10q22.3 transmembrane protein 254 NNMT 0.345 11q23.1 nicotinamide N-methyltransferase NARS 0.344 18q21.31 asparaginyl-tRNA synthetase KCTD3 0.343 1q41 potassium channel tetramerization domain containing 3 RDH10 0.343 8q21.11 retinol dehydrogenase 10 (all-trans) CSGALNACT10.342 8p21.3 chondroitin sulfate N-acetylgalactosaminyltransferase 1 THPO 0.341 3q27 thrombopoietin DLGAP1-AS10.341 18p11.31 DLGAP1 antisense RNA 1 KIAA1549 0.341 7q34 KIAA1549 ATP8B1 0.34 18q21.31 ATPase, aminophospholipid transporter, class I, type 8B, member 1 FAM46A 0.339 6q14 family with sequence similarity 46, member A ZBED1 0.338 Xp22.33;Yp11zinc finger, BED-type containing 1 WDR72 0.337 15q21.3 WD repeat domain 72 RPH3AL 0.337 17p13.3 rabphilin 3A-like (without C2 domains) CNPY2 0.337 12q15 canopy FGF signaling regulator 2 AMBP 0.336 9q32-q33 alpha-1-microglobulin/bikunin precursor PRKAA2 0.335 1p31 protein kinase, AMP-activated, alpha 2 catalytic subunit KIT 0.335 4q12 v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog GPT2 0.335 16q12.1 glutamic pyruvate transaminase (alanine aminotransferase) 2 CYP24A1 0.335 20q13 cytochrome P450, family 24, subfamily A, polypeptide 1 DHTKD1 0.335 10p14 dehydrogenase E1 and transketolase domain containing 1 FECH 0.335 18q21.3 ferrochelatase PNKD 0.334 2q35 paroxysmal nonkinesigenic dyskinesia BPIFA1 0.334 20q11.2 BPI fold containing family A, member 1 CCDC64 0.334 12q24.23 coiled-coil domain containing 64 PDE3A 0.334 12p12 phosphodiesterase 3A, cGMP-inhibited FAM222A 0.333 12q24.11 family with sequence similarity 222, member A PCSK1 0.332 5q15-q21 proprotein convertase subtilisin/kexin type 1 DOCK5 0.332 8p21.2 dedicator of cytokinesis 5 PPIB 0.331 15q21-q22 peptidylprolyl isomerase B (cyclophilin B) SMOC1 0.331 14q24.2 SPARC related modular calcium binding 1 FKBP11 0.331 12q13.12 FK506 binding protein 11, 19 kDa LARP4 0.33 12q13.12 La ribonucleoprotein domain family, member 4 CHL1 0.33 3p26.1 cell adhesion molecule L1-like MCF2L 0.33 13q34 MCF.2 cell line derived transforming sequence-like TMED6 0.33 16q22.1 transmembrane emp24 protein transport domain containing 6 SUDS3 0.329 12q24.23 suppressor of defective silencing 3 homolog (S. cerevisiae) GLCE 0.329 15q23 glucuronic acid epimerase CDH17 0.329 8q22.1 cadherin 17, LI cadherin (liver-intestine) SPTSSA 0.329 14q13.1 serine palmitoyltransferase, small subunit A DNAJC12 0.329 10q22.1 DnaJ (Hsp40) homolog, subfamily C, member 12 MPDU1 0.328 17p13.1-p12mannose-P-dolichol utilization defect 1 TAT 0.327 16q22.1 tyrosine aminotransferase VIMP 0.327 15q26.3 VCP-interacting membrane selenoprotein GLDC 0.327 9p22 glycine dehydrogenase (decarboxylating) AIFM2 0.326 10q22.1 apoptosis-inducing factor, mitochondrion-associated, 2 KCNK3 0.326 2p23 potassium channel, two pore domain subfamily K, member 3 GSTP1 0.324 11q13 glutathione S-transferase pi 1 AKR1C3 0.324 10p15-p14 aldo-keto reductase family 1, member C3 SLC45A4 0.324 8q24.3 solute carrier family 45, member 4 ATP2A3 0.324 17p13.3 ATPase, Ca++ transporting, ubiquitous KIF21A 0.323 12q12 kinesin family member 21A HYAL1 0.322 3p21.31 hyaluronoglucosaminidase 1 MCCC2 0.322 5q12-q13 methylcrotonoyl-CoA carboxylase 2 (beta) ODC1 0.322 2p25 ornithine decarboxylase 1 RIMKLB 0.321 12p13.31 ribosomal modification protein rimK-like family member B CHD1L 0.321 1q12 chromodomain helicase DNA binding protein 1-like COL25A1 0.32 4q25 collagen, type XXV, alpha 1 STARD10 0.32 11q13 StAR-related lipid transfer (START) domain containing 10 AACS 0.32 12q24.31 acetoacetyl-CoA synthetase VAPA 0.319 18p11.22 VAMP (vesicle-associated membrane protein)-associated protein A, 33kDa IFT81 0.319 12q24.13 intraflagellar transport 81 CA8 0.318 8q12.1 carbonic anhydrase VIII ENO3 0.317 17p13.2 enolase 3 (beta, muscle) ISG20 0.317 15q26 interferon stimulated exonuclease gene 20kDa DCTN6 0.317 8p12 dynactin 6 ETS2 0.316 21q22.2 v-ets avian erythroblastosis virus E26 oncogene homolog 2 DECR1 0.314 8q21.3 2,4-dienoyl CoA reductase 1, mitochondrial PCSK6 0.313 15q26.3 proprotein convertase subtilisin/kexin type 6 TRAF2 0.313 9q34 TNF receptor-associated factor 2 MUC5B 0.313 11p15.5 mucin 5B, oligomeric mucus/gel-forming PITX2 0.313 4q25 paired-like homeodomain 2 F7 0.312 13q34 coagulation factor VII (serum prothrombin conversion accelerator) GRAMD1A 0.312 19q13.13 GRAM domain containing 1A BTG1 0.312 12q22 B-cell translocation gene 1, anti-proliferative NOSTRIN 0.311 2q31.1 nitric oxide synthase trafficking ADSSL1 0.311 14q32.33 adenylosuccinate synthase like 1 BAG1 0.311
Load more

Recommended publications
  • Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Screening and identification of key biomarkers in clear cell renal cell carcinoma based on bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignancy of the urinary system. The pathogenesis and effective diagnosis of ccRCC have become popular topics for research in the previous decade. In the current study, an integrated bioinformatics analysis was performed to identify core genes associated in ccRCC. An expression dataset (GSE105261) was downloaded from the Gene Expression Omnibus database, and included 26 ccRCC and 9 normal kideny samples. Assessment of the microarray dataset led to the recognition of differentially expressed genes (DEGs), which was subsequently used for pathway and gene ontology (GO) enrichment analysis.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0337275 A1 Pearlman Et Al
    US 20150337275A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0337275 A1 Pearlman et al. (43) Pub. Date: Nov. 26, 2015 (54) BOCONVERSION PROCESS FOR Publication Classification PRODUCING NYLON-7, NYLON-7.7 AND POLYESTERS (51) Int. C. CI2N 9/10 (2006.01) (71) Applicant: INVISTATECHNOLOGIES S.a.r.l., CI2P 7/40 (2006.01) St. Gallen (CH) CI2PI3/00 (2006.01) CI2PI3/04 (2006.01) (72) Inventors: Paul S. Pearlman, Thornton, PA (US); CI2P 13/02 (2006.01) Changlin Chen, Cleveland (GB); CI2N 9/16 (2006.01) Adriana L. Botes, Cleveland (GB); Alex CI2N 9/02 (2006.01) Van Eck Conradie, Cleveland (GB); CI2N 9/00 (2006.01) Benjamin D. Herzog, Wichita, KS (US) CI2P 7/44 (2006.01) CI2P I 7/10 (2006.01) (73) Assignee: INVISTATECHNOLOGIES S.a.r.l., (52) U.S. C. St. Gallen (CH) CPC. CI2N 9/13 (2013.01); C12P 7/44 (2013.01); CI2P 7/40 (2013.01); CI2P 13/005 (2013.01); (21) Appl. No.: 14/367,484 CI2P 17/10 (2013.01); CI2P 13/02 (2013.01); CI2N 9/16 (2013.01); CI2N 9/0008 (2013.01); (22) PCT Fled: Dec. 21, 2012 CI2N 9/93 (2013.01); CI2P I3/04 (2013.01); PCT NO.: PCT/US2012/071.472 CI2P 13/001 (2013.01); C12Y 102/0105 (86) (2013.01) S371 (c)(1), (2) Date: Jun. 20, 2014 (57) ABSTRACT Embodiments of the present invention relate to methods for Related U.S. Application Data the biosynthesis of di- or trifunctional C7 alkanes in the (60) Provisional application No.
    [Show full text]
  • Rhoa Promotes Epidermal Stem Cell Proliferation Via PKN1-Cyclin D1 Signaling
    RESEARCH ARTICLE RhoA promotes epidermal stem cell proliferation via PKN1-cyclin D1 signaling Fan Wang1, Rixing Zhan2, Liang Chen1, Xia Dai1, Wenping Wang1, Rui Guo1, Xiaoge Li1, Zhe Li1, Liang Wang1, Shupeng Huang1, Jie Shen1, Shirong Li1☯*, Chuan Cao1☯* 1 Department of Plastic and Reconstructive Surgery, Southwestern Hospital, Third Military Medical University, Chongqing, China, 2 School of Nursing, Third Military Medical University, Chongqing, China ☯ These authors contributed equally to this work. * [email protected] (LS); [email protected] (CC) a1111111111 Abstract a1111111111 a1111111111 a1111111111 a1111111111 Objective Epidermal stem cells (ESCs) play a critical role in wound healing, but the mechanism under- lying ESC proliferation is not well defined. Here, we explore the effects of RhoA on ESC pro- liferation and the possible underlying mechanism. OPEN ACCESS Citation: Wang F, Zhan R, Chen L, Dai X, Wang W, Methods Guo R, et al. (2017) RhoA promotes epidermal (+/+) (-/- stem cell proliferation via PKN1-cyclin D1 Human ESCs were enriched by rapid adhesion to collagen IV. RhoA (G14V), RhoA ) signaling. PLoS ONE 12(2): e0172613. (T19N) and pGFP control plasmids were transfected into human ESCs. The effect of RhoA doi:10.1371/journal.pone.0172613 on cell proliferation was detected by cell proliferation and DNA synthesis assays. Induction Editor: Austin John Cooney, University of Texas at of PKN1 activity by RhoA was determined by immunoblot analysis, and the effects of PKN1 Austin Dell Medical School, UNITED STATES on RhoA in terms of inducing cell proliferation and cyclin D1 expression were detected using Received: August 10, 2016 specific siRNA targeting PKN1. The effects of U-46619 (a RhoA agonist) and C3 transferase Accepted: February 6, 2017 (a RhoA antagonist) on ESC proliferation were observed in vivo.
    [Show full text]
  • NDUFAF1 Antibody
    Efficient Professional Protein and Antibody Platforms NDUFAF1 Antibody Basic information: Catalog No.: UPA63763 Source: Rabbit Size: 50ul/100ul Clonality: monoclonal Concentration: 1mg/ml Isotype: Rabbit IgG Purification: Protein A purified. Useful Information: WB:1:1000 ICC:1:50-1:200 Applications: IHC:1:50-1:200 FC:1:50-1:100 Reactivity: Human Specificity: This antibody recognizes NDUFAF1 protein. Immunogen: Synthetic peptide within C terminal human NDUFAF1. This gene encodes a complex I assembly factor protein. Complex I (NADH-ubiquinone oxidoreductase) catalyzes the transfer of electrons from NADH to ubiquinone (coenzyme Q) in the first step of the mitochondrial respiratory chain, resulting in the translocation of protons across the inner mitochondrial membrane. The encoded protein is required for assembly of complex I, and mutations in this gene are a cause of mitochondrial complex I deficiency. Alternatively spliced transcript variants have been observed for Description: this gene, and a pseudogene of this gene is located on the long arm of chromosome 19. Part of the mitochondrial complex I assembly (MCIA) com- plex. The complex comprises at least TMEM126B, NDUFAF1, ECSIT, and ACAD9. Interacts with ECSIT. Interacts with ACAD9. At early stages of com- plex I assembly, it is found in intermediate subcomplexes that contain dif- ferent subunits including NDUFB6, NDUFA6, NDUFA9, NDUFS3, NDUFS7, ND1, ND2 and ND3 Uniprot: Q9Y375 Human BiowMW: 38 kDa Buffer: 1*TBS (pH7.4), 1%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide. Storage: Store at 4°C short term and -20°C long term. Avoid freeze-thaw cycles. Note: For research use only, not for use in diagnostic procedure.
    [Show full text]
  • Molecular Mechanism of ACAD9 in Mitochondrial Respiratory Complex 1 Assembly
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.07.425795; this version posted January 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular mechanism of ACAD9 in mitochondrial respiratory complex 1 assembly Chuanwu Xia1, Baoying Lou1, Zhuji Fu1, Al-Walid Mohsen2, Jerry Vockley2, and Jung-Ja P. Kim1 1Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, USA 2Department of Pediatrics, University of Pittsburgh School of Medicine, University of Pittsburgh, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224, USA Abstract ACAD9 belongs to the acyl-CoA dehydrogenase family, which catalyzes the α-β dehydrogenation of fatty acyl-CoA thioesters. Thus, it is involved in fatty acid β-oxidation (FAO). However, it is now known that the primary function of ACAD9 is as an essential chaperone for mitochondrial respiratory complex 1 assembly. ACAD9 interacts with ECSIT and NDUFAF1, forming the mitochondrial complex 1 assembly (MCIA) complex. Although the role of MCIA in the complex 1 assembly pathway is well studied, little is known about the molecular mechanism of the interactions among these three assembly factors. Our current studies reveal that when ECSIT interacts with ACAD9, the flavoenzyme loses the FAD cofactor and consequently loses its FAO activity, demonstrating that the two roles of ACAD9 are not compatible. ACAD9 binds to the carboxy-terminal half (C-ECSIT), and NDUFAF1 binds to the amino-terminal half of ECSIT. Although the binary complex of ACAD9 with ECSIT or with C-ECSIT is unstable and aggregates easily, the ternary complex of ACAD9-ECSIT-NDUFAF1 (i.e., the MCIA complex) is soluble and extremely stable.
    [Show full text]
  • Angio-Associated Migratory Cell Protein Interacts with Epidermal
    Cellular Signalling 61 (2019) 10–19 Contents lists available at ScienceDirect Cellular Signalling journal homepage: www.elsevier.com/locate/cellsig Angio-associated migratory cell protein interacts with epidermal growth factor receptor and enhances proliferation and drug resistance in human T non-small cell lung cancer cells Shun Yaoa, Feifei Shia, Yingying Wanga,b, Xiaoyang Suna, Wenbo Suna, Yifeng Zhanga, ⁎ ⁎ Xianfang Liuc, Xiangguo Liua,b, , Ling Sua,b, a Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Qingdao, China b Shandong Provincial Collaborative Innovation Center of Cell Biology, School of Life Sciences, Shandong Normal University, Jinan, China c The Department of Otolaryngology Head and Neck Surgery, Shandong Provincial Hospital, Affiliated to Shandong University, Jinan, China ARTICLE INFO ABSTRACT Keywords: Angio-associated migratory cell protein (AAMP) is expressed in some human cancer cells. Previous studies have AAMP shown AAMP high expression predicted poor prognosis. But its biological role in non-small cell lung cancer Proliferation (NSCLC) cells is still unknown. In our present study, we attempted to explore the functions of AAMP in NSCLC Tumorigenesis cells. According to our findings, AAMP knockdown inhibited lung cancer cell proliferation and inhibited lung EGFR cancer cell tumorigenesis in the mouse xenograft model. Epidermal growth factor receptor (EGFR) is a primary Icotinib receptor tyrosine kinase (RTK) that promotes proliferation and plays an important role in cancer pathology. We Doxorubicin found AAMP interacted with EGFR and enhanced its dimerization and phosphorylation at tyrosine 1173 which activated ERK1/2 in NSCLC cells. In addition, we showed AAMP conferred the lung cancer cells resistance to chemotherapeutic agents such as icotinib and doxorubicin.
    [Show full text]
  • Supplemental Figure 1. Vimentin
    Double mutant specific genes Transcript gene_assignment Gene Symbol RefSeq FDR Fold- FDR Fold- FDR Fold- ID (single vs. Change (double Change (double Change wt) (single vs. wt) (double vs. single) (double vs. wt) vs. wt) vs. single) 10485013 BC085239 // 1110051M20Rik // RIKEN cDNA 1110051M20 gene // 2 E1 // 228356 /// NM 1110051M20Ri BC085239 0.164013 -1.38517 0.0345128 -2.24228 0.154535 -1.61877 k 10358717 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 /// BC 1700025G04Rik NM_197990 0.142593 -1.37878 0.0212926 -3.13385 0.093068 -2.27291 10358713 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 1700025G04Rik NM_197990 0.0655213 -1.71563 0.0222468 -2.32498 0.166843 -1.35517 10481312 NM_027283 // 1700026L06Rik // RIKEN cDNA 1700026L06 gene // 2 A3 // 69987 /// EN 1700026L06Rik NM_027283 0.0503754 -1.46385 0.0140999 -2.19537 0.0825609 -1.49972 10351465 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3 // 78465 /// NM_ 1700084C01Rik BC150846 0.107391 -1.5916 0.0385418 -2.05801 0.295457 -1.29305 10569654 AK007416 // 1810010D01Rik // RIKEN cDNA 1810010D01 gene // 7 F5 // 381935 /// XR 1810010D01Rik AK007416 0.145576 1.69432 0.0476957 2.51662 0.288571 1.48533 10508883 NM_001083916 // 1810019J16Rik // RIKEN cDNA 1810019J16 gene // 4 D2.3 // 69073 / 1810019J16Rik NM_001083916 0.0533206 1.57139 0.0145433 2.56417 0.0836674 1.63179 10585282 ENSMUST00000050829 // 2010007H06Rik // RIKEN cDNA 2010007H06 gene // --- // 6984 2010007H06Rik ENSMUST00000050829 0.129914 -1.71998 0.0434862 -2.51672
    [Show full text]
  • Implications in Parkinson's Disease
    Journal of Clinical Medicine Review Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease Silvia Paciotti 1,2 , Elisabetta Albi 3 , Lucilla Parnetti 1 and Tommaso Beccari 3,* 1 Laboratory of Clinical Neurochemistry, Department of Medicine, University of Perugia, Sant’Andrea delle Fratte, 06132 Perugia, Italy; [email protected] (S.P.); [email protected] (L.P.) 2 Section of Physiology and Biochemistry, Department of Experimental Medicine, University of Perugia, Sant’Andrea delle Fratte, 06132 Perugia, Italy 3 Department of Pharmaceutical Sciences, University of Perugia, Via Fabretti, 06123 Perugia, Italy; [email protected] * Correspondence: [email protected] Received: 29 January 2020; Accepted: 20 February 2020; Published: 21 February 2020 Abstract: Ceramides are a family of bioactive lipids belonging to the class of sphingolipids. Sphingolipidoses are a group of inherited genetic diseases characterized by the unmetabolized sphingolipids and the consequent reduction of ceramide pool in lysosomes. Sphingolipidoses include several disorders as Sandhoff disease, Fabry disease, Gaucher disease, metachromatic leukodystrophy, Krabbe disease, Niemann Pick disease, Farber disease, and GM2 gangliosidosis. In sphingolipidosis, lysosomal lipid storage occurs in both the central nervous system and visceral tissues, and central nervous system pathology is a common hallmark for all of them. Parkinson’s disease, the most common neurodegenerative movement disorder, is characterized by the accumulation and aggregation of misfolded α-synuclein that seem associated to some lysosomal disorders, in particular Gaucher disease. This review provides evidence into the role of ceramide metabolism in the pathophysiology of lysosomes, highlighting the more recent findings on its involvement in Parkinson’s disease. Keywords: ceramide metabolism; Parkinson’s disease; α-synuclein; GBA; GLA; HEX A-B; GALC; ASAH1; SMPD1; ARSA * Correspondence [email protected] 1.
    [Show full text]
  • Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-Cell Leukemia
    Author Manuscript Published OnlineFirst on March 27, 2020; DOI: 10.1158/1078-0432.CCR-19-3519 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Constitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell Leukemia Anouchka P. Laurent1,2, Aurélie Siret1, Cathy Ignacimouttou1, Kunjal Panchal3, M’Boyba K. Diop4, Silvia Jenny5, Yi-Chien Tsai5, Damien Ross-Weil1, Zakia Aid1, Naïs Prade6, Stéphanie Lagarde6, Damien Plassard7, Gaelle Pierron8, Estelle Daudigeos-Dubus4, Yann Lecluse4, Nathalie Droin1, Beat Bornhauser5, Laurence C. Cheung3,9, John D. Crispino10, Muriel Gaudry1, Olivier A. Bernard1, Elizabeth Macintyre11, Carole Barin Bonnigal12, Rishi S. Kotecha3,9,13, Birgit Geoerger4, Paola Ballerini14, Jean-Pierre Bourquin5, Eric Delabesse6, Thomas Mercher1,15 and Sébastien Malinge1,3 1INSERM U1170, Gustave Roussy Institute, Université Paris Saclay, Villejuif, France 2Université Paris Diderot, Paris, France 3Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Australia 4Gustave Roussy Institute Cancer Campus, Department of Pediatric and Adolescent Oncology, INSERM U1015, Equipe Labellisée Ligue Nationale contre le Cancer, Université Paris-Saclay, Villejuif, France 5Department of Pediatric Oncology, Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland 6Centre of Research on Cancer of Toulouse (CRCT), CHU Toulouse, Université Toulouse III, Toulouse, France 7IGBMC, Plateforme GenomEast, UMR7104 CNRS, Ilkirch, France 8Service de Génétique, Institut Curie, Paris, France 9School of Pharmacy and Biomedical Sciences, Curtin University, Bentley, Australia 10Division of Hematology/Oncology, Northwestern University, Chicago, USA 11Hematology, Université de Paris, Institut Necker-Enfants Malades and Assistance Publique – Hopitaux de Paris, Paris, France 12Centre Hospitalier Universitaire de Tours, Tours, France 1 Downloaded from clincancerres.aacrjournals.org on September 30, 2021.
    [Show full text]
  • The Role of the Mtor Pathway in Developmental Reprogramming Of
    THE ROLE OF THE MTOR PATHWAY IN DEVELOPMENTAL REPROGRAMMING OF HEPATIC LIPID METABOLISM AND THE HEPATIC TRANSCRIPTOME AFTER EXPOSURE TO 2,2',4,4'- TETRABROMODIPHENYL ETHER (BDE-47) An Honors Thesis Presented By JOSEPH PAUL MCGAUNN Approved as to style and content by: ________________________________________________________** Alexander Suvorov 05/18/20 10:40 ** Chair ________________________________________________________** Laura V Danai 05/18/20 10:51 ** Committee Member ________________________________________________________** Scott C Garman 05/18/20 10:57 ** Honors Program Director ABSTRACT An emerging hypothesis links the epidemic of metabolic diseases, such as non-alcoholic fatty liver disease (NAFLD) and diabetes with chemical exposures during development. Evidence from our lab and others suggests that developmental exposure to environmentally prevalent flame-retardant BDE47 may permanently reprogram hepatic lipid metabolism, resulting in an NAFLD-like phenotype. Additionally, we have demonstrated that BDE-47 alters the activity of both mTOR complexes (mTORC1 and 2) in hepatocytes. The mTOR pathway integrates environmental information from different signaling pathways, and regulates key cellular functions such as lipid metabolism, innate immunity, and ribosome biogenesis. Thus, we hypothesized that the developmental effects of BDE-47 on liver lipid metabolism are mTOR-dependent. To assess this, we generated mice with liver-specific deletions of mTORC1 or mTORC2 and exposed these mice and their respective controls perinatally to
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Evidence for Differential Alternative Splicing in Blood of Young Boys With
    Stamova et al. Molecular Autism 2013, 4:30 http://www.molecularautism.com/content/4/1/30 RESEARCH Open Access Evidence for differential alternative splicing in blood of young boys with autism spectrum disorders Boryana S Stamova1,2,5*, Yingfang Tian1,2,4, Christine W Nordahl1,3, Mark D Shen1,3, Sally Rogers1,3, David G Amaral1,3 and Frank R Sharp1,2 Abstract Background: Since RNA expression differences have been reported in autism spectrum disorder (ASD) for blood and brain, and differential alternative splicing (DAS) has been reported in ASD brains, we determined if there was DAS in blood mRNA of ASD subjects compared to typically developing (TD) controls, as well as in ASD subgroups related to cerebral volume. Methods: RNA from blood was processed on whole genome exon arrays for 2-4–year-old ASD and TD boys. An ANCOVA with age and batch as covariates was used to predict DAS for ALL ASD (n=30), ASD with normal total cerebral volumes (NTCV), and ASD with large total cerebral volumes (LTCV) compared to TD controls (n=20). Results: A total of 53 genes were predicted to have DAS for ALL ASD versus TD, 169 genes for ASD_NTCV versus TD, 1 gene for ASD_LTCV versus TD, and 27 genes for ASD_LTCV versus ASD_NTCV. These differences were significant at P <0.05 after false discovery rate corrections for multiple comparisons (FDR <5% false positives). A number of the genes predicted to have DAS in ASD are known to regulate DAS (SFPQ, SRPK1, SRSF11, SRSF2IP, FUS, LSM14A). In addition, a number of genes with predicted DAS are involved in pathways implicated in previous ASD studies, such as ROS monocyte/macrophage, Natural Killer Cell, mTOR, and NGF signaling.
    [Show full text]